Revelation Biosciences, Inc. (REVB)
NASDAQ: REVB · Real-Time Price · USD
0.755
+0.002 (0.27%)
At close: Nov 22, 2024, 4:00 PM
0.760
+0.005 (0.66%)
After-hours: Nov 22, 2024, 4:46 PM EST
Revelation Biosciences Employees
Revelation Biosciences had 9 employees as of December 31, 2023. The number of employees increased by 3 or 50.00% compared to the previous year.
Employees
9
Change (1Y)
3
Growth (1Y)
50.00%
Revenue / Employee
n/a
Profits / Employee
-$1,723,969
Market Cap
3.24M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 9 | 3 | 50.00% |
| Dec 31, 2022 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Oncternal Therapeutics | 30 |
| InMed Pharmaceuticals | 13 |
| Bio-Path Holdings | 10 |
| Palisade Bio | 9 |
| Virpax Pharmaceuticals | 7 |
| SCWorx | 7 |
| Enveric Biosciences | 7 |
| Oragenics | 5 |
REVB News
- 10 days ago - Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply - Business Wire
- 14 days ago - Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024 - Business Wire
- 2 months ago - Revelation Biosciences' Gemini Induces Dose Dependent Significant Increases in IL-10 - Business Wire
- 3 months ago - Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds - Business Wire
- 3 months ago - Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024 - Business Wire
- 5 months ago - Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity - Business Wire
- 5 months ago - Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini - Business Wire
- 7 months ago - Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024 - Business Wire